Back

AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain

European Heart Journal - Cardiovascular Pharmacotherapy

10 March 2025
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY

Contributors

Felice Gragnano
Felice Gragnano

Author

The University of Campania Luigi Vanvitelli Caserta , Italy

Arturo Cesaro
Arturo Cesaro

Author

Mattia Galli
Mattia Galli

Author

Paolo Calabrò
Paolo Calabrò

Author

Hospital Sant'anna E San Sebastiano Caserta , Italy

You may be interested in
thumbnail
Congress Presentation
Prior anticoagulation experience, bleeding risk, and safety of factor XI inhibition in atrial fibrillation: an analysis of AZALEA-TIMI 71
1 September 2025
thumbnail
ESC TV Today
Episode 17: Coronary sinus reducer - Best strategies to reach LDL cholesterol goals
5 June 2025
thumbnail
Webinar
Are NOACs already outdated? New trends in anticoagulation therapy
12 December 2022
thumbnail
Webinar
ACVC Biomarker Talk Series - Biomarkers in atrial fibrillation
24 November 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources